Enzene Biosciences launches Ranibizumab to treat neovascular AMD
Ranibizumab biosimilar is the company’s seventh biosimilar
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Enzene Biosciences
Enzene Biosciences inaugurates R&D Center with open lab setup in Pune
The new R&D centre signals strategic growth plans, expanded capabilities and enhanced services
Enzene Biosciences launches Bevacizumab
Manufactured using Enzene Biosciences’ patented Continuous Manufacturing Process, Bevacizumab is a biosimilar to Avastin and will…
Enzene Biosciences launches Cetuximab, biosimilar of cancer drug Erbitux
Cetuximab is a therapeutic chimeric monoclonal antibody that is used as a targeted therapy for metastatic colorectal cancer (mCRC)…
Enzene Biosciences begins commercial supply of its biosimilar of Adalimumab
This is the company’s fourth biosimilar launch in recent times
Enzene Biosciences raises $50 million to boost manufacturing capabilities and grow in global markets
The funding round is led by Alkem Laboratories and new investors, Eight Roads Ventures and F-Prime Capital